Minimize Uncertainty – Make Informed Decisions – Succeed

Hematology

Hematology 2025 Review: Deeper Responses, Faster Translation, and the Push to Scale

December 29, 2025Rare blood disorders,FDA hematology approvals,precision medicine,Global hematology market,BioPharma and Tech News,Hematology News,Pharma industry trends,Biopharma investment,Pharma pipeline analysis,Regulatory catalysts,Market access strategy,Hematology market trends,Hematology drug pipeline,Hematology strategy,Blood cancer therapiesHematologic malignancies,Gene and cell therapy in hematology

The throughline of 2025 was not a single modality—it was the convergence of…

by LucidQuest

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Surv BioPharma ¥670 million in Series B for primary malignant bone tumors

December 28, 2025clinical trials,Regulatory,biopharma,sarcoma,Japan,Lucid Diligence Brief,payer access,diligence,venture financing,oncolytic virusAMED

Lucid Diligence Brief: Surv BioPharma ¥670 million in Series B for primary…

by Timos Papagatsias

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Gilead licenses Assembly Bio’s HSV helicase-primase programs

December 27, 2025clinical trials,market access,Regulatory,biopharma,infectious disease,licensing,Lucid Diligence Brief,payer access,diligence,antiviral therapyHSV

Lucid Diligence Brief: Gilead licenses Assembly Bio’s HSV helicase-primase…

by Timos Papagatsias

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Vyriad $25M Series B to take in-vivo CAR-T into clinic

December 26, 2025clinical trials,reimbursement,gene therapy,Regulatory,Cell Therapy,Multiple Myeloma,biopharma,in vivo CAR-T,Lucid Diligence Brief,payer accessdiligence

Lucid Diligence Brief: Vyriad $25M Series B to take in-vivo CAR-T into clinic…

by Timos Papagatsias

Respiratory

Respiratory 2025 Review: From Symptom Control to Disease Modification

December 26, 2025Biologic respiratory drugs,FDA respiratory approvals,precision medicine,Global respiratory market,BioPharma and Tech News,Respiratory News,Pharma industry trends,Biopharma investment,Pharma pipeline analysis,Regulatory catalysts,Market access strategy,Respiratory market trends,Respiratory drug pipeline,Respiratory strategy,Asthma therapiesCOPD drug development,Pulmonary disease treatments

In 2025, respiratory medicine crossed a threshold: biologics entered COPD at…

by LucidQuest

Vaccines

Vaccines 2025 Review: From Emergency Platforms to Durable Public Health Assets

December 26, 2025cancer vaccines,RSV VACCINES,BioPharma and Tech News,mrna vaccines,Vaccine Innovation,Vaccine news,vaccines 2025,vaccine market trends,influenza vaccines,vaccine policyglobal vaccine access,pharmaceutical strategy

In 2025, vaccines moved decisively beyond the COVID-era…

by LucidQuest

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Sanofi moves to buy Dynavax for $2.2B

December 25, 2025Vaccines,clinical trials,market access,Regulatory,biopharma,shingles,Lucid Diligence Brief,payer access,diligence,hepatitis BMedicare Part D

Lucid Diligence Brief: Sanofi moves to buy Dynavax for $2.2B Professional…

by Timos Papagatsias

Cell_Gene_Therapy

Cell and Gene Therapy 2025 Review: Acceleration, Accountability, and the Fight for Scalability

December 25, 2025Manufacturing scale-up,FDA gene therapy approvals,BioPharma and Tech News,Rare Disease Innovation,Biopharma Strategy,Cell and Gene Therapy News,Pharma industry trends,Biopharma investment,Regulatory catalysts,Market access strategy,Cell and gene therapy market trends,Cell and gene therapy pipeline,Advanced therapy medicinal products,Gene therapy developmentCell therapy development,Platform technologies

In 2025, Cell and Gene Therapy moved decisively from proof-of-concept to…

by LucidQuest

Lucid Diligence Brief - Tech

Lucid Diligence Brief: Neurable raises $35M Series A to scale brain-signal AI

December 24, 2025digital health,market access,Regulatory,biopharma,EEG,Brain Computer Interface,Neurotechnology,Lucid Diligence Brief,diligence,privacy,consumer wearablesinvestor brief

Lucid Diligence Brief: Neurable raises $35M Series A to scale brain-signal AI…

by Timos Papagatsias

Neuroscience

Neuroscience 2025 Review: Disease Modification Meets Deliverability

December 24, 2025FDA neuroscience approvals,Market access strategy,precision medicine,Global neuroscience market,BioPharma and Tech News,neurodegenerative diseases,Neuroscience News,Pharma industry trends,Biopharma investment,Pharma pipeline analysis,Neuroscience market trends,Neuroscience drug pipeline,CNS drug development,Mental health therapeutics,Alzheimer’s drug developmentParkinson’s disease therapies,Regulatory catalysts

The defining idea of 2025 was that CNS innovation became an execution…

by LucidQuest

Women's_Health

Women’s Health 2025 Review: From Fragmented Care to Scaled Platforms

December 24, 2025Hormone therapy development,FDA women’s health approvals,precision medicine,Global women’s health market,BioPharma and Tech News,Women's Health News,gynecologic oncology,Pharma industry trends,Biopharma investment,Pharma pipeline analysis,Regulatory catalysts,Women’s health market trends,Women’s health drug pipeline,Reproductive health therapies,Menopause therapeuticsFertility treatments,Maternal health innovation

In 2025, women’s health moved decisively from niche innovation toward scaled…

by LucidQuest

Obesity Weekly News

Obesity Review 2025: The Rise of Oralization, the Muscle Question, and a New Era of Access Pressure

December 23, 2025Global obesity market,BioPharma and Tech News,GLP-1 Therapies,Obesity News,Pharma industry trends,Biopharma investment,Pharma pipeline analysis,Obesity market trends,Obesity drug pipeline,Obesity strategy,Weight loss drug development,Metabolic disease therapeutics,Cardiometabolic drugsChronic disease management,FDA obesity approvals

The defining idea of 2025 was that incretin-era obesity care moved from “how…

by LucidQuest

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required
You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.